No relevant published information exists on the use of fenofibrate during breastfeeding. Because of a concern with disruption of infant lipid metabolism, fenofibrate is best avoided during breastfeeding. An alternate drug is preferred, especially while nursing a newborn or preterm infant. The manufacturer recommends that breastfeeding be avoided during fenofibrate therapy and for 5 days after the final dose.
关于在母乳喂养期间使用非诺贝特，目前尚无相关的已发表信息。由于担心会干扰婴儿的脂质代谢，在母乳喂养期间最好避免使用非诺贝特。首选替代药物，尤其是在哺育新生儿或早产儿期间。制造商建议在非诺贝特治疗期间及最后一剂后5天内避免母乳喂养。
